receptor (uPAR), linking β 1 -integrin to serine proteases. 15 Downregulation of uPAR in colon cancer cells disrupts the uPAR-β 1 -integrin complex without changing the expression of β 1 -integrin. 16 Thus, the associated reduction in degradation of radiolabeled collagen IV is not directly linked to β 1 -integrin. On the other hand, β 1 -integrin may play a direct role in adhesion: maspin, a putative serine protease inhibitor and tumor suppressor, associates with β 1 -integrin in mammary epithelial cells, where its function is not inhibition but rather regulation of adhesion to ECM secreted by these cells. 17 β 1 -Integrin is also linked to matrix metalloproteinases (MMPs) via interactions with tissue inhibitors of metalloproteinases (TIMPs) and with TIMPs through tetraspanins. These interactions play roles in cell survival, apoptosis, and angiogenesis but are independent of MMP activity. 18 Direct interactions between cysteine proteases of the cysteine cathepsin family and β 1 -integrin have not been identified 19 ; however, cysteine proteases, β 1 -integrin, and tetraspanins are present in the same membrane microdomains. Furthermore, these microdomains also contain both serine proteases and MMPs, suggesting that cell-surface proteolytic pathways may be initiated from these membrane regions. In colon cancer cells, for example, cathepsin B has been localized to caveolar lipid rafts through its binding to S100A10, the light chain of the annexin II heterotetramer. 20 Downregulation of caveolin-1 reduces association of cathepsin B, S100A10, urokinase plasminogen activator (uPA), uPAR, and β 1 -integrin with lipid raft fractions of these cells. 21 Furthermore, there is a reduction in invasion through reconstituted basement membrane (rBM) and in degradation of collagen IV. A direct role for β 1 -integrin in degradation of collagen IV has not been demonstrated.
In the present study, we performed functional livecell imaging in real time and used β 1 -integrin short hairpin ribonucleic acid (shRNA) interference and β 1 -integrin function-blocking antibodies to determine whether β 1 -integrins play a role in the degradation of ECM by breast and prostate carcinoma cells. We demonstrate that downregulating β 1 -integrin expression and function significantly reduces degradation of collagen IV, as well as invasion and migration of the breast and prostate carcinoma cells. We further show that there are parallel changes in multiple constituents of proteolytic pathways that have been implicated in ECM degradation, cell migration, and invasion.
Materials and Methods

Cell Culture
BT-549 human breast and DU145 human prostate carcinoma cells were purchased from American Type Culture Collection (Rockville, MD) and cultured in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) and Dulbecco's Minimal Essential Medium (DMEM) supplemented with 10% FBS, respectively (Sigma, St. Louis, MO).
Construction of β β 1 -Integrin shRNA
The plasmid to transcribe β 1 -integrin shRNA contained the sequence for top strand (sense), 5'-GATCCAGCTTCTCTGCTGTTCCTTCTCAAGA-GAAAGGAACAGCAGAGAAGCTCATTTTTTG-GAAA-3', and for bottom strand (antisense), 5'-
Coralville, IA). Two microliters of each oligonucleotide solution (1 µg/µL) were mixed in 46 µL 1X DNA annealing solution. The mixture was heated to 90˚C for 5 minutes and then cooled to 37˚C and incubated at room temperature for 1 hour. The annealed shRNA template insert was ligated into a pSilencer vector, pSilencer3.1-H1Puro (Ambion, Austin, TX), using the standard cloning technique. The identity and orientation of the construct were confirmed by DNA sequencing. The negative control plasmid encodes an shRNA sequence not found in the mouse, human, or rat genome database (Ambion).
Establishment of Stable β β 1 -Integrin shRNA BT-
and DU145 Cell Lines
Parental BT-549 and DU145 cells grown to 60% confluency were transfected with β 1 -integrin shRNA using FuGENE 6 reagent according to the manufacturer's instructions (Roche). Transfected cultures were selected with puromycin (0.5 mg/mL for BT549 cells and 1 µg/mL for DU145 cells) and antibiotic-resistant colonies grown under selection conditions.
Semiquantitative Reverse Transcription-Polymerase Chain Reaction
RNA was isolated from parental cells and cells transfected with β 1 -integrin shRNA using RNeasy Mini Kit (Qiagen) and reverse-transcribed. One milligram of total RNA was annealed with 0.5 mg oligo-dT15 and reverse-transcribed in a 20 mL volume containing 1× reverse transcription buffer (Promega), 0.1 mg/mL bovine serum albumin (BSA), 40 U RNAs in 1mM dNTPs, and 200 U mouse Moloney leukemia virus reverse transcriptase at 37˚C for 120 minutes. PCR Master Mix (Promega) was used for subsequent PCRs. For β 2 -microglobulin (150 bp product) and β 1 -integrin (210 bp product), the amplification conditions were as follows: 25 cycles of 94˚C for 30 seconds, 60˚C for 30 seconds, and 72˚C for 1 minute, followed by a final 10-minute extension at 72˚C. The primer sequences were as follows: β 2 -microglobulin forward, 5'-TTAGCTGT-GCTCGCGCTACTCTCTC-3'; β 2 -microglobulin reverse, 5'-GTCGGATGGATGAAACCCAGACACA-3'; β 1 -integrin forward, 5'-ATCATTCCAATTG-TAGCTGGT-3'; and β 1 -integrin reverse, 5'-TTTTCC-CTCATACTTCGGATT -3' (DNA Technologies).
Preparation of Cell Lysates and Conditioned Media
Cells were grown to approximately 80% confluency in 100 mm dishes and then serum-starved overnight. Cells were harvested using RIPA buffer containing protease inhibitor cocktail (Roche). The conditioned media were collected, centrifuged at 2,000g, and concentrated using Millipore UltraFree 10K filters.
Immunoblotting
Cell lysates or conditioned media were normalized based on DNA determinations and subjected to SDS-PAGE using 12% gels. The protein was transferred to nitrocellulose and then immunoblotted using rabbit antihuman β 1 -integrin polyclonal antibody, 22 monoclonal β-actin antibody (Sigma), monocloanal MMP-14 (R&D Systems), and rabbit antihuman cathepsin B polyclonal antibody 23 in 5% nonfat milk-Tween-Tris buffered saline (T-TBS). Membranes were probed with horseradish peroxidase-labeled secondary antibodies (Pierce) in 5% nonfat milk-T-TBS. Reactive proteins were detected using chemiluminescent kits (Perkin Elmer Life Sciences, Waltham, MA). Cell lysates or conditioned media were also analyzed by a human MMP antibody array (RayBiotech) according to the manufacturer's instructions.
Immunocytochemistry
Cells were grown on rBM (BD Bioscience) -coated coverslips for 16 to 24 hours. Nonpermeabilized cells were stained for surface β 1 -integrin at 4˚C and cells permeabilized with saponin were stained for intracellular β 1 -integrin at room temperature according to our published procedures. 24 Cells were fixed and then blocked for 45 minutes by incubating with PBS containing 2 mg/mL BSA. The cells were incubated with primary antibody (rabbit antihuman β 1 -integrin or preimmune rabbit IgG) for 2 hours. After washing with PBS, the cells were incubated for 1 hour with Texas redconjugated affinity-purified donkey antirabbit IgG containing 5% normal donkey serum (Jackson ImmunoResearch). Cells were then washed, mounted upside down with Slow Fade antifade reagent (Invitrogen Life Technologies) on glass slides, and observed with a Zeiss 510 LSM confocal microscope.
Live-Cell Proteolysis Assay
Glass-bottom microwell 35 mm Petri dishes (MatTek Corporation) were coated with 100 mL of rBM containing 25 mg/mL of DQ-collagen IV (Invitrogen Life Technologies) and placed in a 37˚C incubator for 15 minutes to solidify. Cells (3-4 × 10 4 ) were plated on top of the rBM and incubated at 37˚C for 30 to 60 minutes until they attached. Culture medium with or without β 1 -integrin-blocking antibody mAb 13 (20 µg/mL) was added and the cells cultured for 16 to 24 hours. Preimmune IgG, instead of β 1 -integrin-blocking antibody, was used as one control and rBM-coated coverslips without cells as another control. Degradation products of DQcollagen IV (green) were imaged with a Zeiss LSM 510 META NLO confocal microscope at 488 nm using a 40× water immersion objective. Z-stack images were captured and used to make threedimensional reconstructions of the spheroids (Autovisualize software). Using both Metamorph 6.0 and Volocity 4.2.0 software (Perkin Elmer), the intensity of DQ-collagen IV degradation was measured, normalized to the number of nuclei (stained with Hoechst [Invitrogen Life Technologies] and pseudocolored red), and expressed as fluorescent intensity per cell. Using the Z-stack, the depth to which the cells invaded into the rBM was assessed by the presence of fluorescent cleavage products.
Cathepsin B Activity Assays
Cathepsin B activity assays on cell lysates and overnight serum-free conditioned media were performed as previously described. 25 A 100 µM final con-centration of benzyloxycarbonyl-L-arginyl-L-arginine-4-methyl-7-coumarylamide (Z-Arg-Arg-NHMec) (Bachem) substrate was used and fluorescence was measured in triplicate at 1-minute intervals over a 30-minute period in a Tecan Spectrafluor Plus plate reader at an excitation of 360 nm and an emission of 465 nm. Procathepsin B in the media was activated with 0.4 mg/mL pepsin prior to conducting the assays. DNA assays were performed on each sample, and cathepsin B activity was expressed as pmol/min/µg of DNA. DQcollagen IV substrate (50 µg/mL) was also used as a substrate in this assay and incubated overnight with conditioned media at 37˚C. Following overnight incubation, fluorescence was read at an excitation of 485 nm and an emission of 535 nm and recorded as relative fluorescent units (RFU)/µg DNA. To inhibit cathepsin B activity, we incubated samples in the presence of 10 µM CA074, a highly selective inhibitor of cathepsin B, 26 for 60 minutes prior to performing the assays.
DNA Assay
A 5 µL aliquot of cell lysate was incubated with a 1:10,000 dilution of SYBR Green in DNA assay buffer (100 mM NaCl, 10 mM ethylenediaminetetraacetic acid, pH 7.0, 10 mM Tris) for 15 minutes in the dark. Fluorescence intensities were read at an excitation of 485 nm and an emission of 535 nm. DNA concentrations were determined from a standard curve of known concentrations of salmon sperm DNA (Invitrogen Life Technologies).
Cell Adhesion Assay
Cells were harvested using cell dissociation buffer (Invitrogen Life Technologies) and suspended in serum-free media with 0.1% BSA, and 5 × 10 4 cells were seeded in triplicate on 24-well tissue culture plates coated with 5 µg/mL of either collagen I, collagen IV, laminin, or fibronectin (BD Biosciences). The cells were allowed to attach for 30 minutes, and unattached cells were removed by washing with PBS. Then 2 µM of calcein-acetoxymethyl ester (calcein-AM, Invitrogen Life Technologies) in PBS was added to the cells and incubated for 30 minutes at room temperature. Fluorescent intensities were measured at an excitation of 485 nm and an emission of 535 nm.
Wound Healing Assay
Cells were grown as a monolayer to 100% confluency in 35 mm dishes. Medium was replaced 5 to 6 hours before wounding with RPMI plus /0.1% BSA for BT-549 cells and DMEM plus /0.1% BSA for DU145 cells. A scratch wound was created using a rubber scrapper across the cellular monolayer. Detached cells were removed by washing, and the remaining cells were incubated at 37˚C for 20 hours. The cells were imaged at 5-minute intervals on a Zeiss LSM 510 META NLO microscope, equipped with a controlled environmental chamber that maintains a 5% CO 2 /humidified atmosphere at 37˚C, using a 10× water immersion objective.
Invasion Assays
Invasion assays were performed using Boyden chambers according to our published procedures. 27 Briefly, polycarbonate filters (8 µm pores for BT-549 and 12 µm pores for DU145) (Poretics) were coated with 1% gelatin followed by rBM (50 µg/filter) (BD Biosciences). Cells (2.5 × 10 4 cells in 200 µL) in medium containing 1% FBS in the presence and absence of 20 µg/mL of β 1 -integrin-blocking antibody (mAb 13) 22 were seeded onto the rBM-coated filters and mediuma with 5% FBS was used as the chemoattractant. Following overnight incubation, the filters were removed, air-dried, and stained with Diff-Quik (Dade Behring), and the cells that had invaded were counted and imaged using 10× and 40× objectives.
Statistical Analysis
The statistical significance between control and individual conditions was determined by t-test.
Results
Downregulation of β β 1 -Integrin in Human Breast and Prostate Carcinoma Cells
We investigated the consequences of β 1 -integrin downregulation in human breast (BT-549) and prostate (DU145) carcinoma cells that were stably transfected with shRNA encoding β 1 -integrin. Clones of each cell line were chosen and compared with parental cells and control cells that had been transfected with shRNA encoding a nontargeting sequence. We confirmed that levels of β 1 -integrin RNA and protein were reduced in the shRNA clones, illustrated here for clones BTshβ1-8 and DUshβ1-5 ( Figure 1, A and B ), but not in control cells transfected with nontargeting shRNA (data not shown). Clones in which β 1 -integrin expression was reduced more than in the BTshβ1-8 and DUshβ1-5 clones did not survive beyond three to four passages. Two other clones, BTshβ1-11 and DUshβ1-14, in which β 1 -integrin expression was reduced less than in the BTshβ1-8 and DUshβ1-5 clones, were not evaluated further (data not shown). Staining of the BTshβ1-8 and DUshβ1-5 clones confirmed a reduction in the protein levels of β1-integrin intracellularly ( Figure 1C ) and on the cell surface ( Figure 1D ). Downregulation of β 1 -integrin did not affect cell viability as determined by live/dead assays; both parental cells and clones were 99% viable (data not shown).
Functional Live-Cell Imaging Illustrates that Downregulation and Blocking of β β 1 -Integrin Reduces Degradation of the ECM Protein Collagen IV
We have previously used a functional live-cell proteolysis assay 28 to demonstrate in real time the ability of BT-549 human breast carcinoma and DU145 human Figure 1 . Downregulation of β 1 -integrin in breast and prostate carcinoma cells by short hairpin ribonucleic acid (shRNA) interference. Breast (BT-549) and prostate (DU145) carcinoma cells were stably transfected with a plasmid containing β 1 -integrin shRNA. BT-549 and DU145 clones (BTshβ1-8 and DUshβ1-5 are illustrated here) were established and maintained in selection media as described in experimental procedures. A, Total RNA was isolated from parental cells and clones and subjected to reverse transcription followed by polymerase chain reaction (PCR) using primer sequences to β 1 -integrin and β 2 -microglobulin (as a control for equal loading). PCR products were separated on a 1.2% agarose gel and stained with ethidium bromide. B, Cells were solubilized in lysis buffer without reducing agents, equally loaded, subjected to SDS-PAGE, and immunoblotted with antibodies against β 1 -integrin. Equal loading (normalized by DNA determination) was verified by probing with antibodies against β-actin. Immunoblots are representative of at least three experiments. C, Cells were immunolabeled for intracellular β 1 -integrin with polyclonal β 1 -integrin antibodies at room temperature in the presence of saponin. D, Surface labeling with polyclonal β 1 -integrin antibodies was performed at 4˚C in the absence of saponin. Texas Red-conjugated affinity-purified donkey antirabbit IgG was used as a secondary antibody. Bars = 10 µm.
prostate carcinoma cells to degrade a quenched fluorescent form of collagen IV (ie, DQ-collagen IV). 24, 27, 29 Fluorescent degradation products were observed both pericellularly and intracellularly. Here we examined the degradation of DQ-collagen IV by live BT-549, DU145, BTshβ1-8, and DUshβ1-5 cells. The cells were grown overnight on rBM containing DQ-collagen IV in the presence or absence of the β 1 -integrin-blocking antibody mAb 13 ( Figure 2, A and B) . Preimmune IgG was used as a control and showed no effect on DQcollagen IV degradation (data not shown). Representative single optical sections at the equatorial plane are illustrated in Figure 2 , A and C, and threedimensional reconstructions of the optical sections are shown in Figure 2 , B and D (see also Videos 1 through 4 showing DU145 cells [online version only]). Degradation products of DQ-collagen IV were observed pericellularly and intracellularly. Downregulation of β 1 -integrin expression and function resulted in smaller cellular spheroids and a reduction in proteolysis of DQ-collagen IV (see Figure 2) . Owing to the reduced size of tumor spheroids, we confirmed that proteolysis per cell was also reduced (Figure 3, B and E) . Proteolysis was quantified using our established protocols 28 in which the total integrated intensity of fluorescence throughout an entire Zstack is measured (Metamorph 6.0) and normalized to the total number of nuclei (Volocity 4.2.0) within that Reduced expression or function of β 1 -integrin in BT-549 and DU145 cells decreased the intensity and depth of degradation of DQcollagen IV. BT-549, BTshβ1-8, DU145, and DUshβ1-5 cells were seeded onto glass-bottom dishes coated with recombinant basement membrane-DQ-collagen IV mixture in the presence or absence of the β 1 -integrin-blocking antibody mAb 13 (20 µg/mL). Following overnight incubation at 37˚C, DQ-collagen IV cleavage products (green) were imaged with a Zeiss LSM 510 confocal microscope using a 40× water immersion objective. Nuclei were stained with Hoechst (pseudocolored red here). A and D, Z-stack images were captured and used to make three-dimensional reconstructions of the spheroids (also see Videos 5 through 8 [online version only]). B and E, Using both Metamorph 6.0 and Volocity 4.2.0 softwares (Perkin Elmer, Waltham, MA), the intensity of DQ-collagen IV degradation was measured, normalized to the number of nuclei, and expressed as normalized integrated intensity per cell. C and F, The depth over which proteolysis occurs in the Z-stack of each cell line was recorded. Graphs are representative of at least three experiments and presented as mean ± SD. **p < .01. SD bars are not depicted in B and E because the values are negligible.
Z-stack 28 to determine proteolysis per cell. The reduction in both spheroid size and proteolysis was more extensive when BTshβ1-8 or DUshβ1-5 cells were also incubated with the β 1 -integrin-blocking antibody mAb 13. The depth to which the cells invaded was assessed by measuring the z-axis distance over which green fluorescence products of proteolysis were observed (see Figure 3 and Videos 5 through 8 showing DU145 cells [videos with online version only]). Reduced degradation of DQ-collagen IV corresponded to reduced invasion (see Figure 3 , C and F, respectively), suggesting a role for β 1 -integrin in invasion of tumor cells via degradation of the ECM. We should indicate that the larger impact observed in the cells inhibited by β 1 -integrin antibodies versus cells transfected with β 1 -integrin shRNA is because the mAb 13-blocking antibody, which is specific for β 1 -integrin, inhibits all accessible β 1 -integrin molecules, whereas the shRNA inhibition does not knock down β 1 -integrin completely.
Downregulation and Blocking of β β 1 -Integrin Reduces Tumor Cell Invasion
We further investigated whether β 1 -integrin is required for these cells to invade through rBM. Cells were grown on rBM-coated filters for 24 hours, and the cells that invaded through the filters were stained ( pore filters, respectively. Downregulation of β 1 -integrin reduced invasion of BTshβ1-8 cells by 74% and DUshβ1-5 cells by 46%. The β 1 -integrinblocking antibody mAb 13 was more effective in reducing invasion of BT-549 and DU145 cells than was shRNA. Invasion of the BT-549 and DU145 cells was reduced by 95% and 63%, respectively. These data indicate that β 1 -integrin is involved in invasion of breast and prostate carcinoma cells through rBM in vitro.
Downregulation of β β 1 -Integrin Decreases Secretion of Procathepsin B
The reductions in ECM degradation by β 1 -integrin downregulated cells suggest that β 1 -integrin expression and function may regulate the expression and activity of proteolytic enzymes. Our previous studies revealed that secretion of procathepsin B from breast fibroblasts is reduced in the presence of β 1 -integrin-blocking antibodies. 30 Here we found that secretion of procathepsin B (43/46 kDa) was decreased in BTshβ1-8 cells (Figure 5A ), an effect that was not observed in the prostate cancer cells stably transfected with β1-integrin shRNA (data not shown). There was a corresponding increase in intracellular mature cathepsin B (ie, 31 kDa single chain and 25/26 plus 5 kDa double chain) in BTshβ1-8 cells. Cathepsin B activity assays confirm the immunoblotting data; there was an increase in active cathepsin B intracellularly and a decrease in secretion of pepsin-activatable procathepsin B in the BTshβ|1-8 cells ( Figure 5B ). In addition, we analyzed the ability of the conditioned media to degrade DQcollagen IV in vitro in the presence and absence of the highly selective cathepsin B inhibitor CA074 ( Figure 5C) . 26 There was a reduction in degradation of DQ-collagen IV by the conditioned media of BTshβ1-8 cells compared with BT-549 cells. The degradation of DQ-collagen IV was partially inhibited by CA074, confirming that cathepsin B participates in the extracellular degradation of DQcollagen IV. Furthermore, the level of DQ-collagen IV degradation in the parental and β 1 -integrin downregulated cells in the presence of CA074 was comparable, implicating secreted cathepsin B in the extracellular degradation of this ECM protein.
Downregulation of β β 1 -Integrin Decreases MMP-14 Expression and Secretion of MMP-13, TIMP-1, and TIMP-2 and Increases Secretion of TIMP-3
Given that inhibition of cathepsin B did not abolish the degradation of DQ-collagen IV, we also investigated the effects of β1-integrin downregulation on the expression and secretion of MMPs, the family of proteases most extensively linked to ECM degradation. We found that expression of MMP-14 was reduced in both β1-integrin downregulated breast and prostate cancer cells ( Figure 6A ). In addition, using antibody array analysis, we observed that the secretion of MMP-13 was reduced in β 1 -integrin downregulated prostate cancer cells but not in β 1 -integrin downregulated breast cancer cells ( Figure   6B ). There was also a decrease in secretion of TIMP-1 and -2 and an increase in secretion of TIMP-3 from the prostate cancer cells. These data indicate differential roles for β 1 -integrin in the regulation of MMP and TIMP expression and secretion that is dependent on the tumor cell type.
Downregulation of β β 1 -Integrin Reduces Adhesion to Collagen I and IV and Migration
We investigated the effects of β 1 -integrin on adhesion and migration of BT-549 and DU145 cells. Adhesion of BTshβ1-8 and DUshβ1-5 cells to collagen I and IV, but not to fibronectin and laminin, was reduced compared with that of parental cells ( Figure 7 , A and B, respectively). We also investigated the effect of β 1 -integrin downregulation on cell migration in wound healing assays. During the 24 hours after wounding, migration of the cells was imaged at 5-minute intervals. Parental BT-549 and DU145 cells migrated faster than did BTshβ1-8 and DUshβ1-5 cells. Although both parental and β 1 -integrin downregulated BT-549 cells migrated as individual cells into the wounded (cellfree) areas, there was more migration of parental cells than BTshβ1-8 cells after 20 hours ( Figure 7C ). DU145 parental cells moved collectively as a sheet of cells and had nearly closed the wound after 20 hours, whereas only a few DUshβ1-5 cells had moved into the wounded areas (see Figure 7C ). These data indicate that β 1 -integrin is involved in the adhesion and migration of both breast and prostate cancer cells.
Discussion
β 1 -Integrin facilitates signaling events that promote ECM adhesion, migration, and degradation, thereby supporting tumorigenesis. Given the complexity of ECM, multiple families of proteases (serine, cysteine, and metallo-) participate in ECM remodeling and degradation. Indeed, numerous studies have linked β 1 -integrin expression to alterations in proteases; however, this study is the first to use functional imaging on Figure 5 . Secretion of procathepsin B was reduced in β1-integrin downregulated BT-549 cells. A, BT-549 and BTshβ1-8 cell lysates and overnight serum-free conditioned media were equally loaded, analyzed by SDS-PAGE, and immunoblotted with an anticathepsin B antibody; lysates were immunoblotted with an antiactin antibody as a loading control. Immunoblots are representative of at least three experiments. B and C, Cell lysates and media were assayed for cathepsin B activity against Z-Arg-Arg-NHMec substrate, and activity was recorded as pmol/min/µg DNA. D, Media were assayed for cathepsin B activity against DQ-collagen IV substrate, in the absence (black bars) and presence (white bars) of the highly selective cathepsin B inhibitor CA074, and activity was recorded as relative fluorescent units (RFU)/µg DNA. Graphs are representative of at least three experiments and presented as mean ± SD. **p < .01.
live tumor cells to show the effects of downregulation and/or blocking the function of β 1 -integrin on collagen IV degradation by a network of proteases in both breast and prostate cancer cells. These findings are also accompanied by a decrease in cell adhesion to and invasion through collagen IV-containing matrix. Collagen IV, the structural backbone of the basement membrane, interacts with integrins and serves as scaffolding for the binding of other basement membrane components. 31 We have previously demonstrated that a network of proteases, including MMPs, serine protease plasmin, and cysteine protease cathepsin B, participate in the degradation of collagen IV in breast, colon, and prostate carcinoma cells. 27, 32 In the current study, downregulation of β 1 -integrin expression and/or function revealed differential effects on protease expression and secretion depending on the tumor cell type. For example, in β 1 -integrin downregulated breast cancer cells, secretion of procathepsin B was reduced, an effect not seen in prostate cancer cells. β 1 -Integrin-blocking antibodies also reduces secretion of procathepsin B by breast fibroblasts, and, conversely, β 1 -integrin-activating antibodies stimulate secretion of procathepsin B by these cells. 30 In highly invasive melanoma cells grown in collagen I, inhibition of β 1 -integrin activity by blocking antibodies reduces the secretion of both pro-and mature forms of cathepsin B. 33 A functional link between cathepsin B and β 1 -integrin is also seen in angiogenic signaling where antiangiogenic endostatin, a fragment of collagen VIII that is generated by cathepsin B, 34 blocks α 5 β 1 integrin function. 35 Interestingly, we recently found that cathepsin B and β 1 -integrin colocal- . Two millimolars of calcein AM in PBS was added to the adherent cells for 30 minutes at room temperature. Fluorescent intensities were measured at 485/535 nm and expressed as relative fluorescent units (RFU). Graphs are representative of at least three experiments, and data are presented as mean ± SD. *p < .05; **p < .01. C, Wound healing assays were performed on 100% confluent live cells in 35 mm dishes. Prior to wounding, cells were incubated in serum-free media containing 0.1% bovine serum albumin for 5 to 6 hours. After the wounds were made, detached cells were removed by washing and adherent cells were incubated at 37˚C for 24 hours and then imaged by phase-contrast microscopy using a Zeiss LSM 510 META NLO microscope with a 10× immersion objective. Images are representative of at least three experiments. Bar = 50 µm.
ize to caveolae of endothelial cells during differentiation of these cells into tube-like structures in vitro (unpublished data, 2008), a process associated with degradation of collagen IV (unpublished data). Cathepsin B has also been found to colocalize with β 1 -integrin along with uPA and its receptor uPAR in the caveolae of HCT 116 cells, an association mediated by caveolin-1 expression. 21 Given that cathepsin B can activate pro-uPA to uPA, 36 caveolae may serve as an initiating site for cell surface proteolysis.
Although β 1 -integrin downregulation did not affect cathepsin B in prostate cancer cells, there were effects on MMPs and TIMPs. We show that downregulation of β1-integrin reduces expression of MMP-14, also observed in breast cancer cells; reduces secretion of MMP-13 and TIMP-1 and -2; and increases secretion of TIMP-3. In human chondrocytes, β 1 -integrinblocking antibodies inhibit the induction of MMP-13 expression in these cells by type I collagen. 37 Conversely, induction and activation of MMP-13 are augmented by β 1 -integrin-activating antibodies in human skin fibroblasts grown on a collagen I matrix, 38 thus indicating that MMP-13 expression and activation in these cells are regulated by the interaction between β 1 -integrin and the ECM. The decrease in MMP-14 expression and TIMP-2 secretion in the β 1 -integrin downregulated prostate cancer cells is interesting since MMP-14 is an activator of MMP-2 and TIMP-2 acts as a linker protein for the activation of pro-MMP-2 by MMP-14. 39 In ovarian carcinoma cells, β 1 -integrin was shown to stimulate the activation of pro-MMP-2 by MMP-14. 40 Although we also observed a decrease in TIMP-1 secretion, TIMP-3 secretion was increased in β 1 -integrin downregulated prostate cancer cells. The association between TIMP-3 and β 1 -integrin is not clear; however, TIMP-3 is the only TIMP to completely inhibit the sphingosine-1-phosphate-induced and α 2 β 1 -dependent invasion of endothelial cells in collagen matrices. 41 A reduction in TIMP-1 expression was previously reported in β 1 -integrin downregulated DU145 cells, 42 and TIMP-1 is hypothesized to interact with the CD63/β 1 -integrin signaling complex, which is required for cell survival and motility. 18 The association of β 1 -integrin with MMP-14 also involves cell migration. In endothelial cells, MMP-14 participates in cooperation with β 1 -integrin during migration of these cells on various ECMs. 39 MMP-14 was also found colocalized with β1-integrin in actin-rich, "collagenolysis-free" leading edges of migrating fibrosarcoma and breast carcinoma cells grown on a three-dimensional collagen matrix. 43 It was suggested that at the leading edges of these migrating cells, adhesion and remodeling of the ECM that facilitate forward movement. 43 Here we show a perturbation in the migration of β 1 -integrin downregulated cells, an effect likely associated with the observed changes in protease and inhibitor expression and secretion.
Our data also revealed that a reduction in β 1 -integrin expression and activity in both breast and prostate carcinoma cells decreased cell migration and adhesion to type I and IV collagen. These data complement previous studies that show that the interaction of human prostate cancer cells PC3 with the collagen matrix of bone is mediated by collagen-binding integrin α 2 β 1 and is enhanced by ttransforming growth factor β 1 . 44, 45 Moreover, bombesin-mediated activation of pro-MMP-9 in PC3 cells is facilitated by ligation of β 1 -integrin to collagens I and IV and fibronectin, 46 which increases uPA expression, membrane-linked uPA activity, and activation of Src and phosphatidylinositol 3-kinase, thereby augmenting invasion of these cells. 46 Our findings, however, revealed no effect of β 1 -integrin on the binding of breast and prostate cancer cells to fibronectin or laminin. Similar observations are reported in cell adhesion assays using squamous cell carcinoma cells. 47 On the other hand, several studies show a role for β 1 -integrin adhesion to fibronectin and laminin, including several cell signaling events. 3 It is plausible that the lack of effect of β 1 -integrin downregulation on adhesion to fibronectin and laminin can be explained by integrin redundancy, as reported for adhesion of breast cancer cells to fibronectin or vitronectin. 48 Thus, our study using functional imaging of live cells demonstrates an involvement for β 1 -integrin expression in the degradation of collagen IV via procathepsin B secretion and activity, MMP-14 expression, and MMP-13 and TIMP-1, -2, and -3 secretion. Involvements of α integrins that interact with β 1 -integrin during collagen IV degradation are currently being investigated. In addition, other mechanisms that contribute to the proteolysis of ECM, such as the urokinase plasmin(ogen) cascade and signaling pathways involving p21-activated kinase, 49 will be examined with respect to their roles in β 1 -integrin-mediated ECM degradation and invasion of tumor cells.
